Bicycle Therapeutics Shares Rise 8% After Continuation of BT8009 Development
By Chris Wack
Bicycle Therapeutics shares were up 8% at $22.63 after the company said it will proceed with its plan to expedite development of BT8009 for metastatic bladder cancer following recent discussions with the U.S. Food and Drug Administration.
The biotechnology company has aligned with the FDA on a Phase 2/3 registrational trial that has a design allowing for potential accelerated approval in untreated and previously treated metastatic bladder cancer.
Bicycle Therapeutics plans to initiate the trial in the first quarter of 2024.
The Phase 2/3 trial will assess BT8009 in untreated metastatic bladder cancer and previously treated metastatic bladder cancer. Discussions with the FDA about the design of the confirmatory trial for previously treated metastatic bladder cancer are ongoing.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 11, 2023 10:53 ET (14:53 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom